First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
Steven J. Lemery(Center for Drug Evaluation and Research), Richard Pazdur(United States Food and Drug Administration), Patricia Keegan(Center for Drug Evaluation and Research)
Cited by 657
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k